Treatment of Viral Encephalitis in Cytomegalovirus Encephalitis

This protocol addresses viral encephalitis occurring in the specific context of cytomegalovirus (CMV) encephalitis — a clinical scenario that calls for a particular, evidence-based antiviral strategy distinct from general viral encephalitis management.

Clinical scenario: Viral encephalitis with cytomegalovirus encephalitis as the underlying aetiology. The recommended therapeutic approach in this setting is based on evidence in affected patient populations and differs meaningfully from empiric encephalitis management.

Treatment approach

The recommended regimen involves a combination of two specific intravenous antiviral agents given concurrently. The complete protocol — including agent selection, dosing, schedule, duration, and follow-on maintenance — is available in the full structured regimen.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1086/589747

Cytomegalovirus: the combination of ganciclovir plus foscarnet is recommended (B-III); cidofovir is not recommended, because its ability to penetrate the blood-brain barrier has been poorly studied.
A combination of ganciclovir (5 mg/kg intravenously every 12 h) and foscarnet (60 mg/kg intravenously every 8 h or 90 mg/kg intravenously every 12 h) for 3 weeks, followed by maintenance therapy, is recommended and has led to success in HIV-infected patients, with improvement or stabilization in 74% of 31 patients with either cytomegalovirus encephalitis or myelitis.

View source ↗